Haemonetics Corporation (HAE) - 10-K Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Fiscal Year End: April 3, 2004 (53-week fiscal year)
Industry: Medical Devices / Blood Processing Technology
Business Overview: Haemonetics designs, manufactures, and markets automated systems and single-use disposables for the collection, processing, and surgical salvage of blood. The company operates as a single segment, organized into two product families: Donor Products (plasma, platelet, and red cell collection) and Patient Products (surgical blood salvage). Approximately 65% of revenues are generated outside the United States, with significant exposure to the Japanese Yen and Euro.
Key Financial Metrics (Fiscal 2004)
| Metric | Fiscal 2004 | Fiscal 2003 | Change |
|---|---|---|---|
| Net Revenues | $364.2 million | $337.0 million | +8.1% |
| Gross Profit | $172.1 million | $154.7 million | +11.3% |
| Gross Margin | 47.3% | 45.9% | +140 bps |
| Operating Income | $45.9 million | $37.5 million | +22.4% |
| Operating Margin | 12.6% | 11.1% | +150 bps |
| Net Income | $29.3 million | $28.4 million | +3.3% |
| Diluted EPS | $1.19 | $1.13 | +5.3% |
| Cash & Equivalents | $118.1 million | $49.9 million | +136.7% |
| Total Debt | $58.3 million | $70.6 million | -17.4% |
| Working Capital | $185.6 million | $122.9 million | +51.0% |
| Current Ratio | 2.9 | 2.2 | N/A |
Material Changes vs. Prior Period
- Revenue Growth Drivers: Revenue increased 8.1%, driven by a 5.2% favorable impact from foreign exchange and volume increases in red cell, blood bank, and surgical product lines. This was partially offset by a decline in plasma product volumes.
- Plasma Market Volatility: The company lost its largest U.S. plasma customer, Alpha Therapeutic Corporation, following its acquisition by Baxter International in October 2003. Baxter closed 38 of 41 Alpha centers, resulting in an estimated $9.0 million revenue loss for fiscal 2005. Haemonetics filed for binding arbitration against Baxter regarding assumed supply contracts.
- Cost Management: Operating expenses increased 7.7% due to foreign exchange and a $2.7 million severance charge from a workforce reorganization (4% reduction). However, R&D expenses decreased 8.8% due to project prioritization.
- Tax Rate: The effective tax rate increased to 36.0% in 2004 from 26.5% in 2003. The prior year's lower rate included a $4.0 million tax refund.
- Liquidity: Cash and cash equivalents more than doubled to $118.1 million, supported by strong operating cash flow of $74.6 million and a reduction in debt.
Guidance, Outlook, and Risks
- Product Pipeline: R&D focus is shifting to the CardioPAT (cardiovascular surgical salvage), an enhanced MCS platelet collection platform, and the Red Cell Collector. Limited market release for CardioPAT and CE marking for the Red Cell Collector are expected in the second half of fiscal 2005.
- Market Outlook:
- Plasma: Oversupply of source plasma is expected to persist into fiscal 2005, reducing collection activity. Consolidation in the industry remains a risk.
- Red Cell: Growth is expected to continue driven by blood shortages and the adoption of double red cell collection technology.
- Surgical: The high blood loss market is mature/declining due to improved surgical techniques, while the orthopedic market (OrthoPAT) remains a growth driver.
- Key Risks:
- Customer Concentration: Sales to the Japanese Red Cross Society accounted for 24.1% of net revenues in 2004.
- Foreign Exchange: Approximately 65% of sales are in foreign currencies; a strengthening U.S. dollar negatively impacts results.
- Regulatory: Dependence on FDA and international regulatory approvals for new technologies (e.g., pathogen reduction).
- Legal: Outcome of arbitration against Baxter regarding Alpha Therapeutic contracts is uncertain.
Investor Verification Checklist
- Plasma Revenue Exposure: Verify the specific impact of the Alpha/Baxter acquisition on future plasma revenue and the status of the arbitration claim.
- Japanese Red Cross Dependency: Assess the risk associated with 24.1% of revenue coming from a single customer (Japanese Red Cross).
- Foreign Exchange Hedging: Review the effectiveness of forward contracts in mitigating currency risk, given the 5.2% revenue boost from FX in 2004.
- Inventory Valuation: Confirm the adequacy of reserves for excess and obsolete inventory, particularly related to plasma collection devices and disposables no longer supported by the Alpha customer base.
- R&D Milestones: Monitor the timeline for the CardioPAT and Red Cell Collector launches to ensure they meet the projected fiscal 2005 market entry dates.